| Time |
Session |
|
|
09:30
11:00
|
-
-
"Therapeutic Advances in Bronchiectasis: Prof Anne B Chang
Queensland University of Technology; Department of Respiratory and Sleep Medicine, Queensland Children’s Hospital, Brisbane; and Menzies School of Health Research, Darwin, Australia
Bronchiectasis is coming of age with the realisation of its burden of disease on patients and health systems, combined with increased research and pharmaceutical interest with fresh therapeutics.
Early therapeutics focused on using antibiotics. While the first use of inhaled antibacterial solutions for bronchiectasis occurred in 1892[1], specific inhaled antibiotics usage was initially extrapolated from CF data in the 1990s until the first RCT that targeted adults with bronchiectasis.[2] Treatment of bronchiectasis has advanced markedly since the adoption of Cole’s paradigm,[3] which has now evolved into the contemporary vortex model. Using this framework, therapeutic advances include optimised airway clearance strategies, long-term macrolide therapy, inhaled and systemic antibiotics for selected patients, and improved treatment pathways for exacerbations and chronic infection, rehabilitation, muco-active agents (for a subset) as well as specific treatment for different phenotypes.[4] Both neutrophil dominant and eosinophil phenotypes have emerged as a leading therapeutic focus. These have culminated in the development of a therapeutic pipeline of dipeptidyl peptidase 1 (DPP 1) inhibitors including brensocatib, verducatib and HSK31858. Together, these interventions have reduced exacerbation frequency and improved quality of life in appropriately selected patients, and DPP 1 has a disease-modifying effect. In parallel, greater attention is being given to nutrition, vaccination, comorbidities, and adherence to self-management plans, all of which contribute to treatment effectiveness.
With respect to antibiotics, several pharmaceutical companies undertook large multicenter RCTs (e.g. AIR-BX, RESPIRE, ORBIT). Despite demonstrating reductions in airway bacterial load, these trials yielded mixed results for their primary clinical endpoints (mostly exacerbations).[5] While possible explanation for the variance include the heterogeneity in microbiome baseline status and geography[5], the latest systematic review (20 RCTs) generally favoured inhaled antibiotics (vs placebo) with reduced exacerbation frequency (RR=0.78, 95%CI 0.68, 0.91) and improved and QoL-Bronchiectasis respiratory symptom score (mean difference=2.51, 95%CI 0.44-4.31).[6]
Bronchiectasis management has thus evolved from symptom control toward a more targeted approach. Emerging strategies are increasingly focused on precision medicine, including better risk stratification, biomarker development, and use of imaging and microbiologic data to guide therapy. Overall, therapeutic progress in bronchiectasis reflects a shift toward earlier intervention, prevention of exacerbations, and more personalized care. Despite these advances, important gaps remain in pediatric bronchiectasis, where high-quality evidence is still limited and most treatment decisions are extrapolated from adult data.
References
1 Osler W. The principles and practice of medicine: designed for the use of practitioners and students of medicine. New York: D. Appleton and Company, 1892.
2 Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med 2000; 162: 481-485.
3 Cole PJ. Inflammation: a two edged sword. The model of bronchiectasis. Eur J Respir Dis Suppl 1986; 147: 6-15.
4 Tramontano A, Caporaso M, Macciocchi G, et al. New Perspectives in the Treatment of Bronchiectasis. Arch Bronconeumol 2026; Jan 9:S0300-2896(26)00004-9.
5 Mac Aogain M. Beyond ORBIT: Mapping the Constellation of Pseudomonas Endotypes in Bronchiectasis Clinical Trials. Am J Respir Crit Care Med 2025; 211: 1321-1323.
6 Cordeiro R, Choi H, Haworth CS, et al. The Efficacy and Safety of Inhaled Antibiotics for the Treatment of Bronchiectasis in Adults: Updated Systematic Review and Meta-Analysis. Chest 2024; 166: 61-80.
"
-
Co-morbidities are highly prevalent in non-cystic fibrosis bronchiectasis and serve as major drivers of disease severity, healthcare utilization, and mortality. While traditional clinical assessments focus primarily on pulmonary architecture, emerging evidence demonstrates that multimorbidity profoundly impacts patient prognosis, necessitating a shift toward comprehensive, multi-organ evaluation. This talk synthesizes current global registry data and international cohorts to examine the prevalence, pathophysiological mechanisms, and prognostic implications of respiratory, systemic, and psychological co-morbidities. Concomitant airway diseases such as COPD and asthma independently predict increased exacerbation frequency, accelerated FEV1 decline, and reduced survival, while chronic rhinosinusitis correlates with altered airway microbiology and type 2 inflammation. Systemic and metabolic complications—including diabetes mellitus, Vitamin D deficiency, and gastroesophageal reflux managed with high-dose proton pump inhibitors—are heavily associated with worse radiological severity, increased hospitalizations, and elevated all-cause mortality. Furthermore, bronchiectasis significantly escalates the risk of cardiovascular events and progressive renal decline, where renal impairment independently triples mortality risk. Dedicated risk stratification tools, such as the Bronchiectasis Aetiology Comorbidity Index (BACI), outperform generic comorbidity indices in predicting long-term survival. Recognizing, screening, and actively managing these extra-pulmonary and overlapping conditions is essential for delivering personalized care and improving long-term patient outcomes.
-
Ballroom 3, Lower Ground Floor
|
|
11:00
12:00
|
-
AI Radiomics for the Early Detection of Lung Cancer
Background: Lung cancer remains the leading cause of cancer-related mortality in Canada. Low-dose computed tomography (LDCT) screening frequently detects small or ground-glass opacity nodules that are challenging to assess for malignancy. This study aimed to develop a radiomics-based machine-learning model to predict the future malignant behaviour of these difficult nodules.
Materials and Methods: Small nodules were drawn from three lung cancer screening datasets: PanCan (n=2,085 participants; N=10,381 nodules), ILST (n=1,082 participants; N=2,389 nodules), and DLCS (n=1,373 participants; N=2,009 nodules). A self-attention deep-learning model was trained for nodule segmentation, and axial masks were reconstructed into three-dimensional core nodule masks. Radiomics features were extracted from four discrete regions: the nodule core and surrounding regions, including core-plus-edge, shell, and shell-without-blood-vessel masks. Machine-learning models were developed and compared with the Brock model.
Results: At a low false-positive rate of 10%, the ML-radiomics models demonstrated superior sensitivity to the Brock model across all nodule types in the external validation set. Both approaches identified malignant nodules at baseline that would not have otherwise received interventional management and predicted malignancy up to 2 years before clinical confirmation.
Conclusion: A pipeline integrating deep-learning segmentation with ML-radiomics can accurately classify subcentimetre nodules up to approximately 2 years before clinical confirmation of malignancy in lung cancer screening.
Keywords: Lung Cancer, LDCT Screening, Radiomics, Machine Learning, Deep Learning
-
Lung cancer is a major health problem in the in the Asia-Pacific, with the region accounting for over 60% of global lung cancer diagnoses and deaths. Compared to Western counterparts, lung cancer in Asia exhibits distinct and unique characteristics. Key differences between lung cancer in Asia and outside Asia include a much higher prevalence in never-smokers, younger age of onset, and significantly higher rates of EGFR mutations (30-40% vs. 7-15% in the West). Over 30% of Asian lung cancer patients are never-smokers, with that number rising to over 50% in East Asian women. This is significantly higher than in Western countries. Asian patients have a much higher prevalence of EGFR mutations (30-40%) compared to Caucasian patients (7-15%). Conversely, KRAS mutations which are commonly smoking-related are less frequent in Asian patients (8-10%) than in Western populations (20-30%). While smoking is still a major cause, especially in men (half of the world's smokers live in Asia), never-smoker cases are highly driven by indoor air pollution (biomass fuel), ambient particulate matter (PM2.5), and passive smoking. Asian patients are generally diagnosed at a younger age, with early-onset lung cancer incidents rising, particularly in China, India, and Indonesia. Adenocarcinoma is the most common histological subtype in Asia, often appearing as ground-glass opacities. Asian patients tend to have a better prognosis. However, access to molecular diagnostics and newer, more effective treatments varies significantly between high-income countries (e.g., Japan, South Korea, Australia) and low-to-middle-income countries in the region.
-
"Background
Lung cancer is the leading cause of cancer-related mortality in the Asia Pacific (APAC) region, accounting for approximately 60% of global cases. The demographic of lung cancer in this region is shifting, with increasing incidence among younger individuals, non-smokers, and women. Driven by diverse risk factors including air pollution, occupational hazards, genetic predisposition, and household cooking fumes, there is a pressing need for personalized approaches to screening, diagnosis, and treatment.
Early Detection & Screening
Low-dose computed tomography (LDCT) screening has been instrumental in shifting detection toward early-stage disease. While global trials primarily focus on heavy smokers, regional data indicates that genetic factors play a critical role. A nationwide screening program in Taiwan demonstrated that individuals with a family history of lung cancer have a higher detection rate of early-stage disease (89.6%) compared to heavy smokers (66.1%). This targeted screening approach has led to a significant stage shift and a projected 53% reduction in lung cancer mortality.
Targeted Therapy & Immunotherapy
Recent phase III trials evaluating targeted therapies (such as osimertinib, amivantamab plus lazertinib, and lorlatinib) and immunotherapies (including pembrolizumab and neoadjuvant nivolumab) show that clinical efficacy and toxicity profiles in Asian cohorts are highly consistent with global populations. Subgroup analyses from landmark trials, including FLAURA2, MARIPOSA, KEYNOTE-189, and CheckMate 816, confirm that APAC patients derive comparable progression-free survival (PFS), overall survival (OS), and pathological complete response (pCR) benefits from these advanced treatment modalities.
Conclusions & Future Challenges
Despite the biological efficacy of advanced treatments mirroring global outcomes, the APAC region faces unique, systemic challenges. Wide regional variations in healthcare infrastructure, drug pricing, and reimbursement criteria—along with underrepresentation in global clinical trials—create significant disparities in early diagnosis and treatment access. Overcoming these socio-economic barriers and optimizing management strategies in resource-limited settings remain the primary challenges for improving lung cancer survival rates across the Asia Pacific region.
"
-
Ballroom 3, Lower Ground Floor
|
|
14:00
15:00
|
-
Respiratory medicine's evidence base is skewed by Asia's near-absence from clinical trials, and that this is not merely an equity problem but a scientific one — Asia holds close to 60% of the world's population and therefore the largest absolute number of pneumonia deaths, yet the diversity within the continent is treated as a single category. The diversity extends to management and inflammatory profiles in ARDS. This has implications with personalized care and trials. Precision therapy already shows access disparities in Asia mirroring those documented for molecular testing in lung cancer elsewhere. Chronic disease phenotypes diverge as well — COPD risk centers more on biomass fuel and prior TB exposure than smoking; lung cancer shows higher rates of non-smoking adenocarcinoma and EGFR mutation; bronchiectasis trends toward post-TB incidence and a dry phenotype with lower bacterial burden; asthma sub-phenotypes vary country to country.
But this diversity in Asia are also opportunities for research. This can be done by leveraging existing data sources and collecting new registry data (retrospective or prospective) to establish disease burden. One can start locally and then link data across sites. Collaborate for team science, and participate in pragmatic comparative-effectiveness and implementation trials that embed into routine care without placebo or drug preparation are also opportunities. Given limited resources, researchers should choose questions no one has answered locally and collect only the key data that can be done routinely during clinical practice. Professional meetings are an important route to multi-country teams and research. One key element is the need to invest in training physicians in research methods so that they can lead research in their own country. ATS MECOR (Methods in Epidemiologic, Clinical and Operations Research) is one model for building that capacity.
-
Respiratory medicine increasingly relies on evidence generated across different populations. Yet clinical findings from one region may not fully describe patients in another. Asia is highly diverse, and differences may exist both between Asian and Western patient groups and among populations within Asia.
As an example of diversity within Asia, the frequency of EGFR mutations in lung adenocarcinoma varies across Asian populations. Turning to COPD, selected observational studies from Asia, Europe and the United States suggest differences in body mass index, chronic bronchitis and exacerbation history across the groups studied. These findings should not be taken as uniform characteristics of all Asian patients. Breathlessness, reduced daily activity and long-term outcomes also deserve attention, even when exacerbations are less frequent.
Another major challenge is underdiagnosis. Studies from Japan, Korea and China have identified gaps in COPD diagnosis or previous spirometry use. Efforts to address these gaps must take local healthcare systems and resources into account.
Japan's Health Japan 21 programme includes a national target to reduce COPD mortality. To support this goal, the Japanese Respiratory Society is pursuing COMORE-By2032, an ongoing initiative that links public awareness and earlier medical visits with spirometry, smoking cessation and continued care.
Global evidence is essential, but improving COPD care also requires locally appropriate action and collaboration across the Asia-Pacific region.
-
-
Ballroom 4, Lower Ground Floor
|